Automated insulin delivery with mylife™ CamAPS® FX and the mylife™ YpsoPump® insulin pump 2 February 2023 Advertorial Ypsomed Australia is pleased to introduce the mylife™ CamAPS® FX App – a new automated insulin dosing algorithm app that is housed on a smartphone for use with the mylife™ YpsoPump® insulin pump and is approved in Australia for use from ages 1 year and older*. How does mylife™ CamAPS® FX work? mylife™ CamAPS® FX is an adaptive, hybrid closed-loop solution that enables users of the mylife™ YpsoPump® insulin pump to better manage their glucose levels and to benefit from a uniquely adaptive and responsive algorithm that is housed on the user’s smartphone. The system: Automatically adjusts insulin delivery on the insulin pump based on Dexcom G6 sensor glucose readings Constantly learns and adapts to ever-changing insulin needs for each individual Adjusts to day and night, day-to-day and week-to-week variations in insulin requirements, and compensates for over- and under-dosing of the meal-time bolus Can be personalised with adjustable personable glucose targets Allows users to deliver a meal-time bolus directly from their smartphone discreetly and conveniently. There are three key components to the hybrid closed-loop system: mylife™ YpsoPump® insulin pump Compatible Android phone (visit www.dexcom.com/compatibility to ensure your phone and OS is compatible) Dexcom G6 sensor/transmitter. mylife™ YpsoPump®: small, smart design and discreet to wear Small and light – weighs only 83 grams1 Comfortable and discreet to wear day and night For more information about mylife™ CamAPS® FX and the mylife™ YpsoPump®, contact Ypsomed Australia – email [email protected], call 1800 447 042 (Free Call) or visit https://www.mylife-diabetescare.com *Additional age restrictions may apply depending on the chosen continuous glucose monitor and insulin pump. 1. Waldenmaier D. et al.: First User Experiences With a Novel Touchscreen-Based Insulin Pump System in Daily Life of Patients With Type 1 Diabetes Experienced in Insulin Pump Therapy. Journal of Diabetes Science and Technology. 2019;13(1):96-102. doi: 10.1177/1932296818785386 Disclaimer: Always read the label and use only as directed. Consult your healthcare professional to see if this product is right for you. CamAPS® is a registered trademark of CamDiab Ltd. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license. Other trademarks and trade names are those of their respective owners.
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Good Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading
Blog 22 July 2026 Living Out Loud: how Australia spoke up for National Diabetes Week 2026 From 12 to 18 July, Australians living with diabetes, alongside their carers, researchers, health professionals and clinicians, did something powerful. They... Continue Reading
News 20 July 2026 Response to media reports from 60 Minutes, The Sydney Morning Herald, and The Age regarding regulation of diabetes technologies The safety of people living with diabetes must always come first. For many Australians, technologies such as insulin pumps and continuous glucose monitors are essential tools that help prevent dangerous high and low blood glucose levels, reduce the daily burden of living with diabetes and improve long-term health outcomes. For some individuals they can be life-changing or even life-saving. Continue Reading
